The Price of 154 Drug Formulations Revised by NPPA
The National Pharmaceutical
Pricing Authority has fixed/ revised the prices of 154 drug formulation packs
as on 19th July, 2012. Of these, Ceiling Prices have been fixed in respect
of 138 drug formulation packs, which are applicable to all manufacturers.
Company specific Non-ceiling prices have been fixed in case of 16 packs of drug
formulation.
The prices have been fixed
for the first time in respect of 33 drug formulation packs. No price increases
have been allowed in respect of 17 packs keeping the consumer interest in view.
In the case of 80 packs, the prices have been reduced from the existing level
ranging from 0.12% to 37.76%. In the case of 24 packs, prices have been increased
ranging from 0.64% to 31.40% to accommodate the unavoidable increase in input
Raw material cost, Conversion cost, Packing Charges and Packing Material Norms
in order to make availability of the essential drugs to the consumers. In
absolute term the price reduction ranges from `0.04 to `3.52 per pack.
The drug formulation
containing the Vitamin C & its derivatives have been revised on Suo-moto basis to pass on the benefit of reduction in bulk
drug prices to consumers as manufacturers failed to send price revision
application to NPPA within the stipulated time limit of 30 days as per DPCO,
1995. In these cases the prices have been reduced ranging from 0.12% to 37.76%
than the existing price resulting lower price for Vitamin C formulations which
will benefit the consumers at a large.
The revised prices have
been fixed strictly per the provisions of the Drugs (Prices Control) Order
(DPCO), 1995 and the guidelines in this regard. The revised price lists are to
be issued by the manufacturers/importers under sub paragraph (3) of paragraph
14 of the DPCO, 1995 and the compliance should be reported to the
government/NPPA, State Drug Control Authorities and distributors, wholesalers
and retailers or any other agent.
The prices were fixed in
respect of derivative formulations of the bulk drugs namely, Aspirin with Rosuvastatin
(Cardiovascular), Cefotaxime (Antibacterial), Chlorpromazine with combination
(Antipsychotic), Vitamine E (Tocopheryl)
(Vitamin E Supplement), Streptomycin
with Penicillin (Antibiotic), Norfloxacin (Antibacterial), Vitamin C with combination (Vitamin C Supplement and Antioxidant),
Sulphadoxine with combination (Antimalarial), Dexamethasone with combination (Anti-inflamatory), Multivitamin with Vitamin C (Vitamin
Supplement) and Insulin formulations etc.
Necessary Gazette
Notification Orders to this affect have been issued separately.
Some leading National News
Papers recently reported that NPPA has increased the price of Insulin
formulations. This is factually incorrect and baseless. NPPA has not increased
the price of any insulin formulation. It is pertinent to state that the major
manufacturers/importers of diabetic drug Insulin, such as M/s Eli Lilly, M/s. Cadila and M/s. Lupin M/s. Biocon etc applied for upward
revision in the retail price of Insulin. However, keeping the interest of large
number of consumer’s, the prices of insulin formulations have been maintained
at the existing level by suitably adjusting the profit margin in order to
ensure the abundant availability of Insulin formulations at reasonable prices.
[Source: Ministry of Chemicals and Fertilizers, PIB Press
Release dated 24 July 2012]